Effect of Vericiguat on Endpoint Events in Acute Coronary Syndrome( ACS ）Patients With Ejection Fraction < 45%

Conditions: Acute Coronary Syndrome; Heart Failure With Reduced Ejection Fraction Interventions: Drug: Vericiguat Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials